Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01530373 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 2026 to Jul 2027
    • Study completion date: Sep 2027 to Sep 2028
    v20
  2. Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 6 to 110
    • Site details revised
    v19
  3. Primary completion date: Jul 2025 to Jul 2026
    • Study completion date: Sep 2026 to Sep 2027
    v18
  4. Primary completion date: Jul 2023 to Jul 2025
    • Study completion date: Sep 2024 to Sep 2026
    v17
  5. Re-verified, no change to tracked fieldsv16
Show 14 earlier versionsHide 14 earlier versions
  1. Primary completion date: Jul 2021 to Jul 2023
    • Study completion date: Sep 2021 to Sep 2024
    v15
  2. Primary endpoints revised (2)
    • Eligibility criteria expanded, about 37 words
    v14
  3. Re-verified, no change to tracked fieldsv13
  4. Enrollment target: estimated 110 to confirmed 6
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v12
  5. Eligibility criteria shortened, about 26 words
    • Site contact updated
    v11
  6. Primary completion date: Jul 2020 to Jul 2021
    • Study completion date: Sep 2020 to Sep 2021
    • Site contact updated
    v10
  7. Primary completion date: Jul 2018 to Jul 2020
    • Study completion date: Sep 2019 to Sep 2020
    v9
  8. Primary completion date: Jul 2017 to Jul 2018
    • Study completion date: Sep 2017 to Sep 2019
    v8
  9. Primary completion date: Jul 2016 to Jul 2017
    • Study completion date: Sep 2016 to Sep 2017
    v7
  10. Re-verified, no change to tracked fieldsv6
  11. Primary endpoints revised (2)v5
  12. Site contact updatedv4
  13. Primary completion date: Jul 2014 to Jul 2016
    • Study completion date: Sep 2014 to Sep 2016
    • Eligibility criteria shortened, about 15 words
    • Study description expanded, about 4 words
    v3
  14. Primary completion date: Jul 2013 to Jul 2014
    • Study completion date: Sep 2013 to Sep 2014
    • Secondary endpoints: 4 to 3
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in reducing hot flashes, compared with clonidine (a medication often used for treating hot flashes).
Trial Details
NCT Number NCT01530373
Lead Sponsor University of Arkansas
Conditions
(from sponsor)		 Hot Flashes, Breast Cancer
Related terms Breast Neoplasms, Hot Flashes
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov